摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(dimethylamino)ethyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate | 1158802-65-3

中文名称
——
中文别名
——
英文名称
2-(dimethylamino)ethyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate
英文别名
2-(dimethylamino)ethyl 2-[4-[[2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl]methyl]phenyl]acetate
2-(dimethylamino)ethyl 2-(4-((2-amino-4-methyl-6-(pentylamino)pyrimidin-5-yl)methyl)phenyl)acetate化学式
CAS
1158802-65-3
化学式
C23H35N5O2
mdl
——
分子量
413.563
InChiKey
XPQGDFIMNJFDAE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    610.6±65.0 °C(predicted)
  • 密度:
    1.121±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    30
  • 可旋转键数:
    13
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    93.4
  • 氢给体数:
    2
  • 氢受体数:
    7

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Compounds
    申请人:AstraZeneca AB
    公开号:US08268990B2
    公开(公告)日:2012-09-18
    The present invention provides compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    本发明提供了式(I)中的化合物,其中R1、R2、R3和R4如规范中所定义,并且其药学上可接受的盐,以及其制备过程,包含它们的制药组合物和它们在治疗中的使用。
  • NOVEL COMPOUNDS
    申请人:Bennett Nicholas J.
    公开号:US20130045955A1
    公开(公告)日:2013-02-21
    The present invention provides compounds of formula (I) herein R 1 , R 2 , R 3 and R 4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    本发明提供了公式(I)的化合物,其中R1、R2、R3和R4如规范中所定义,并且其药学上可接受的盐,以及它们的制备方法,含有它们的制药组合物和它们在治疗中的使用。
  • Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers
    申请人:Bennett Nicholas J.
    公开号:US08765939B2
    公开(公告)日:2014-07-01
    The present invention provides compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    本发明提供了式(I)化合物,其中R1、R2、R3和R4如规范中所定义,以及其药学上可接受的盐,以及制备它们的方法,含有它们的制药组合物以及它们在治疗中的用途。
  • Novel Compounds
    申请人:BENNETT Nicholas J.
    公开号:US20090209524A1
    公开(公告)日:2009-08-20
    The present invention provides compounds of formula (1) wherein R 1 , R 2 , R 3 and R 4 are as defined in the specification, and pharmaceutically acceptable salts thereof, as well as processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    本发明提供了式(1)的化合物 其中R1、R2、R3和R4如规范中所定义,并且其药学上可接受的盐,以及制备它们的方法,含有它们的制药组合物以及它们在治疗中的使用。
  • PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ASTHMA, COPD, ALLERGIC RHINITIS, ALLERGIC CONJUNCTIVITIS, ATOPIC DERMATITIS, CANCER, HEPATITIS B, HEPATITIS C, HIV, HPV, BACTERIAL INFECTIONS AND DERMATOSIS
    申请人:AstraZeneca AB
    公开号:EP2222648A1
    公开(公告)日:2010-09-01
查看更多